Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Seamless, Clinical Trial to Investigate the Safety and Efficacy of Multiple Doses of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy

Next Previous
X
Search
Trial Profile

A Seamless, Clinical Trial to Investigate the Safety and Efficacy of Multiple Doses of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elsunersen (Primary)
  • Indications Encephalopathy; Epilepsy
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EMBRAVE
  • Sponsors Praxis Precision Medicines

    • Most Recent Events

    • 04 Sep 2024 According to a Praxis Precision Medicines media release, data from this study will be presented at the International League Against Epilepsy 15th European Epilepsy Congress which is taking place in Caravaggio on September 10.
    • 13 Aug 2024 According to a Praxis Precision Medicines media release, company plans to advance the program within the US and expand to Europe later in 2024.First arm of the global confirmatory study initiated in Brazil
    • 08 Jan 2024 According to a Praxis Precision Medicines media release, company has an upcoming meeting with the FDA to discuss next steps in developing elsunersen.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top